pyrazines has been researched along with Opportunistic Infections in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alinari, L; Bond, DA; Maddocks, K | 1 |
| Morrison, VA | 1 |
| Grünberg, K; Sonneveld, P; Wittgen, BP; Wondergem, MJ; Zweegman, S | 1 |
| Bahlis, NJ; Barr, PM; Cooper, BW; Dowlati, A; Fu, P; Gerson, SL; Horvath, N; Koc, ON; Lazarus, HM; Snell, MR | 1 |
| Cantaffa, R; Carillio, G; Kropp, M; Lamberti, AG; Molica, S; Piro, E | 1 |
| Bostrom, BC; Eckroth, E; Gaynon, PS; Malvar, J; Messinger, YH; Sposto, R; van der Giessen, J | 1 |
| Hashimoto, N; Okamoto, S; Sadahira, K; Tsukada, Y; Ueda, T; Yokoyama, K | 1 |
2 review(s) available for pyrazines and Opportunistic Infections
| Article | Year |
|---|---|
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Forecasting; Gastrointestinal Neoplasms; Hemorrhage; Humans; Immunologic Factors; Lymphocytosis; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Neoplasm Proteins; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Salvage Therapy | 2019 |
Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Bacterial Infections; Boronic Acids; Bortezomib; Female; Humans; Immune Tolerance; Male; Middle Aged; Mycoses; Neoplasms; Opportunistic Infections; Pyrazines; Tumor Necrosis Factor-alpha; Virus Diseases | 2014 |
2 trial(s) available for pyrazines and Opportunistic Infections
| Article | Year |
|---|---|
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nervous System Diseases; Neutropenia; Opportunistic Infections; Pyrazines; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2009 |
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
Topics: Adolescent; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Boronic Acids; Bortezomib; Child; Child, Preschool; Dexamethasone; Doxorubicin; Female; Humans; Infant; Kaplan-Meier Estimate; Male; Opportunistic Infections; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Recurrence; Remission Induction; Treatment Outcome; Vincristine; Young Adult | 2012 |
3 other study(ies) available for pyrazines and Opportunistic Infections
| Article | Year |
|---|---|
Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multiple Myeloma; Opportunistic Infections; Pneumocystis carinii; Pneumonia, Pneumocystis; Pyrazines | 2009 |
Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib.
Topics: Antineoplastic Agents; Antiprotozoal Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Immunosuppressive Agents; Italy; Leishmania donovani; Leishmaniasis, Visceral; Male; Middle Aged; Multiple Myeloma; Opportunistic Infections; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2012 |
Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy.
Topics: Adult; Aged; Antifungal Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytochrome P-450 Enzyme System; Dexamethasone; Diabetes Complications; Drug Synergism; Female; Humans; Inactivation, Metabolic; Incidence; Itraconazole; Male; Middle Aged; Multiple Myeloma; Mycoses; Opportunistic Infections; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Proton Pump Inhibitors; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy | 2012 |